Press Release: Invenshure Announces GeneMatters acquisition as part of a $60M Series C financing of Genome Medical
Press Release: Invenshure Announces GeneMatters acquisition as part of a $60M Series C financing of Genome Medical
Press Release: Invenshure Announces GeneMatters acquisition as part of a $60M Series C financing of Genome Medical
新闻稿：Invenshure宣布收购GeneMatters，作为对Genome Medical 6000万美元C系列融资的一部分
Invenshure Announces GeneMatters acquisition as part of a $60M Series C financing of Genome Medical
Invenshure宣布收购GeneMatters公司，作为对Genome Medical公司6000万美元C系列融资的一部分
Financing Led by Casdin Capital with Participation from Leading Life Sciences Investors.
融资由Casdin Capital牵头，主要生命科学投资者参与。
PR Newswire
美通社
MINNEAPOLIS, Aug. 30, 2021
明尼阿波利斯，2021年8月30日
MINNEAPOLIS, Aug. 30, 2021 /PRNewswire/ -- Invenshure announced today that GeneMatters has been acquired by Genome Medical, the leading nationwide genomic care delivery company. Founded by Invenshure and Jill Davies, a genetic counselor and thought leader in the field, GeneMatters is a Minneapolis-based company providing telehealth genetic counseling and software solutions that increase access to genetic services.
明尼阿波利斯，2021年8月30日/美通社/--Invenshure今天宣布，GeneMatters已经被全国领先的基因组护理提供公司Genome Medical收购。GeneMatters由Invenshure和吉尔·戴维斯(Jill Davies)创立，后者是该领域的遗传顾问和思想领袖，总部位于明尼阿波利斯，提供远程健康遗传咨询和软件解决方案，以增加获得遗传服务的机会。
Invenshure previously announced an investment into GeneMatters by Casdin Capital in November of 2020 and this announcement further validates the company's technology and position in the marketplace. "While it has been rewarding to be a part of the progression of the company from start up to sale, perhaps the biggest satisfaction is our positive contribution to the impact of healthcare delivery," said Invenshure's Co-CEO, Troy Kopischke. "We are excited for the entire GeneMatters team and look forward with great anticipation to the power of the Genome Medical-GeneMatters combination and the continued transformation of genetic healthcare."
Invenshure之前在2020年11月宣布了Casdin Capital对GeneMatters的投资，这一声明进一步证实了该公司的技术和市场地位。Invenshure的联席首席执行官特洛伊·科皮施克(Troy Kopischke)说：“虽然成为公司从启动到销售的过程中的一部分是值得的，但最大的满足感可能是我们对医疗保健服务的影响做出了积极贡献，”Invenshure联合首席执行官特洛伊·科皮施克(Troy Kopischke)说。我们为整个GeneMatters团队感到兴奋，并满怀期待地期待着Genome Medical-GeneMatters合并的力量以及遗传保健的持续变革。“
With the strategic addition of GeneMatters, Genome Medical will expand its clinical capacity and expertise across key clinical areas. Two prominent virtual genetics companies are being brought together, led by industry innovators who offer unmatched knowledge. Both companies share a similar mission and have a relentless dedication to providing the best patient care, customer solutions and service.
随着GeneMatters的战略性增加，基因医疗公司将扩大其在关键临床领域的临床能力和专业知识。两家著名的虚拟遗传学公司正在合并，由提供无与伦比知识的行业创新者领导。两家公司有着相似的使命，并坚持不懈地致力于提供最好的患者护理、客户解决方案和服务。
"It has been a great journey partnering with Invenshure to build GeneMatters, with a mission to increase access to genetic counseling and to support patient decision-making," said Jill Davies, Co-founder and President of GeneMatters. "We are thrilled to be joining forces with Genome Medical, a leader in the delivery of genomic medicine, who shares our mission, vision and passion for patient care."
GeneMatters的联合创始人兼总裁吉尔·戴维斯说：“与Invenshure合作建立GeneMatters是一次伟大的旅程，其使命是增加获得遗传咨询的机会，并支持患者的决策。”我们很高兴能与基因医学领域的领先者Genome Medical公司联手，后者与我们在病人护理方面有着共同的使命、愿景和热情。“
GeneMatters will operate as a wholly owned subsidiary of Genome Medical Holding Company, with a focus on expanding the delivery of genetic services to community health systems and other partners. It will operate under the GeneMatters name and provide exceptional service to its customers.
GeneMatters将作为Genome Medical Holding Company的全资子公司运营，重点是扩大向社区卫生系统和其他合作伙伴提供基因服务。它将以GeneMatters的名义运营，并为其客户提供卓越的服务。
The Series C financing was led by Casdin Capital, a committed and leading long-term investor in life sciences and genomics. New investors GV (formerly Google Ventures) and Amgen Ventures participated in this round alongside Genome Medical's existing investors, including Perceptive Advisors, LRVHealth, Echo Health Ventures, Kaiser Permanente Ventures, Canaan Partners, Illumina Ventures, Revelation Partners, HealthInvest Equity Partners, Avestria Ventures, Flywheel Ventures, Dreamers Fund and Blue Ivy Ventures.
C系列融资由卡斯丁资本公司(Casdin Capital)牵头，卡斯丁资本公司是生命科学和基因组学领域坚定和领先的长期投资者。新的投资者GV(前身为Google Ventures)和Amgen Ventures与Genome Medical的现有投资者一起参与了本轮融资，其中包括Perceptive Advisors公司、LRVHealth公司、Echo Health Ventures公司、Kaiser Permanente Ventures公司、Canaan Partners公司、Illumina Ventures公司、Revation Partners公司、HealthInvest Equity Partners公司、Avestria Ventures公司、飞轮公司、Dreamers Fund公司和Blue Ivy Ventures公司。
About Invenshure
关于Invenshure
Invenshure is a venture catalyst company focused on the creation and development of healthcare and biotechnology companies - built around novel IP from leading scientists and institutions. To learn more about Invenshure and our companies, visit www.Invenshure.com.
Invenshure是一家风险催化剂公司，专注于医疗保健和生物技术公司的创建和发展-围绕领先科学家和机构的新型知识产权而建立。欲了解有关Invenshure和我们公司的更多信息，请访问www.Invenshure.com。
About GeneMatters
关于GeneMatters
GeneMatters is a leading provider of telehealth genetic counseling and software solutions to increase access to genetic services. We deliver customizable solutions to hospitals, health networks, genetic testing labs and biopharmaceutical organizations to extend the capacity of existing genetic counseling teams, support new programs and increase patient engagement with genetic services. Our genetic expertise spans oncology, reproductive, cardiovascular and rare diseases. Founded in 2016 by Invenshure and Jill Davies, with a mission to increase patient access, GeneMatters is committed to outstanding service delivery, unwavering quality standards, high patient satisfaction and technology to simplify care. To learn more, visit gene-matters.com and follow @GeneMatters on Twitter Linkedin
GeneMatters是一家领先的远程健康遗传咨询和软件解决方案提供商，旨在增加获得遗传服务的机会。我们为医院、健康网络、基因检测实验室和生物制药组织提供可定制的解决方案，以扩展现有遗传咨询团队的能力，支持新项目，并提高患者对基因服务的参与度。我们的基因专长涵盖肿瘤学、生殖、心血管和罕见疾病。GeneMatters由Invenshure和Jill Davies于2016年创立，使命是增加患者的接触，致力于提供出色的服务、坚定不移的质量标准、高患者满意度和简化护理的技术。要了解更多信息，请访问gene-matters.com并在Twitter LinkedIn上关注@GeneMatters
View original content:https://www.prnewswire.com/news-releases/invenshure-announces-genematters-acquisition-as-part-of-a-60m-series-c-financing-of-genome-medical-301365146.html
查看原始content:https://www.prnewswire.com/news-releases/invenshure-announces-genematters-acquisition-as-part-of-a-60m-series-c-financing-of-genome-medical-301365146.html
SOURCE Invenshure, LLC
Source Invenshure，LLC
/Web site: http://invenshure.com
网址：http://invenshure.com
(END) Dow Jones Newswires
(完)道琼通讯社
August 30, 2021 09:15 ET (13:15 GMT)
2021年8月30日东部时间09：15(格林尼治标准时间13：15)